- Investing.com
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Metrics to compare | NEU | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNEUPeersSector | |
---|---|---|---|---|
P/E Ratio | 12.8x | −3.1x | −0.6x | |
PEG Ratio | 0.11 | 0.00 | 0.00 | |
Price/Book | 6.9x | 1.6x | 2.6x | |
Price / LTM Sales | 7.8x | 4.5x | 3.1x | |
Upside (Analyst Target) | 127.8% | 163.8% | 55.4% | |
Fair Value Upside | Unlock | 28.5% | 10.2% | Unlock |